Back to UBS Group AG UBS Group AG

HRTXHRTX
30 quarters

Position history for UBS Group AGUBS Group AG's holdings in HERON THERAPEUTICS INC

Yes. Ubs holds 2,997,073 shares of HRTX (Heron Therapeutics), worth $1.3M, as of its Q2 2026 13F filing. It increased the position by 711,190 shares (+31.1%) from Q1 2026. Ubs has held HRTX in every 13F on record since Q1 2019, 30 quarterly filings.

Current Value

$1.3M

Current Shares

3M

Total Value Change

-$110,250

Total Shares Change

+2.9M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
3M
+31.1%
$1.3M0.0%$0.43
32
2026-Q1
Increased
2.3M
+9.3%
$1.8M0.0%$0.80
28
2025-Q4
Decreased
2.1M
-28.7%
$2.7M0.0%$1.30
0
2025-Q3
Decreased
2.9M
-7.9%
$3.7M0.0%$1.26
0
2025-Q2
Increased
3.2M
+1906.4%
$6.6M0.0%$2.07
44
2025-Q1
Decreased
158,739
-0.5%
$349,2260.0%$2.20
0
2024-Q4
Increased
159,476
+87.1%
$243,9980.0%$1.53
25
2024-Q3
Decreased
85,253
-48.9%
$169,6530.0%$1.99
0
2024-Q2
Increased
166,793
+49.7%
$583,7760.0%$3.50
34
2024-Q1
Decreased
111,394
-8.3%
$308,5610.0%$2.77
0
2023-Q4
Increased
121,476
+92.6%
$206,5090.0%$1.70
36
2023-Q3
Decreased
63,066
-8.7%
$64,9570.0%$1.03
0
2023-Q2
Increased
69,037
+23.8%
$80,0830.0%$1.16
18
2023-Q1
Increased
55,768
+51.2%
$84,2090.0%$1.51
20
2022-Q4
Decreased
36,893
-58.0%
$92,2330.0%$2.50
0
2022-Q3
Increased
87,887
+990.3%
$372,0000.0%$4.22
38
2022-Q2
Decreased
8,061
-96.6%
$22,0000.0%$2.79
0
2022-Q1
Decreased
234,120
-26.7%
$1.3M0.0%$5.72
0
2021-Q4
Increased
319,257
+28.7%
$2.9M0.0%$9.13
33
2021-Q3
Increased
248,108
+2957.4%
$2.7M0.0%$10.69
42
2021-Q2
Decreased
8,115
-94.5%
$126,0000.0%$15.52
0
2021-Q1
Increased
147,904
+12.5%
$2.4M0.0%$16.21
29
2020-Q4
Increased
131,450
+43.5%
$2.8M0.0%$21.17
35
2020-Q3
Decreased
91,584
-19.9%
$1.4M0.0%$14.82
0
2020-Q2
Decreased
114,379
-8.7%
$1.7M0.0%$14.71
0
2020-Q1
Increased
125,320
+27.2%
$1.5M0.0%$11.74
32
2019-Q4
Decreased
98,536
-59.1%
$2.3M0.0%$23.50
0
2019-Q3
Increased
240,848
+34.0%
$4.5M0.0%$18.50
35
2019-Q2
Increased
179,708
+215.8%
$3.3M0.0%$18.59
43
2019-Q1
First report
56,903
-
$1.4M0.0%$24.44
0

Other major holders of HRTX: FRANKLIN TEMPLETON INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used